428863-50-7 ((2S)-1-((2S)-6-氨基-2-((羟基(4-苯基丁基)膦)氧基)己酰基)吡咯烷-2-羧酸,Certolizumab pegol)

(2S)-1-((2S)-6-氨基-2-((羟基(4-苯基丁基)膦)氧基)己酰基)吡咯烷-2-羧酸;赛妥珠单抗;

(2S)-1-((2s)-6-amino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)pyrrolidine-2-carboxylic acid;CERTOLIZUMAB PEGOL;Cdp870;Cimzia;Immunoglobulin, anti-(human tumor necrosis factor alpha) fab' fragment (human-mouse monoclonal cdp870 heavy chain), disulfide with human-mouse monoclonal cdp870 light chain, pegylated;Pha 738144;Unii-umd07X179e;L-Proline, 1-(6-amino-2-((hydroxy(4-phenylbutyl)phosphinyl)oxy)-1-oxohexyl)-, (S)-;CERONAPRIL [JAN];HY-106816;CHEBI:177391;SQ 29,852;CERONAPRIL;1-((2S)-6-Amino-2-hydroxyhexanoyl)-L-proline, hydrogen (4-phenylbutyl)phosphonate (ester);(S)-1-(6-Amino-2-((hydroxy(4-phenylbutyl)phosphinyl)oxy)-1-oxohexyl)-L-proline;Q27293516;(2S)-1-[(2S)-6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid;CERONAPRIL [WHO-DD];Ceronaprilum [INN-Latin];CS-0026611;120122-26-1;DB-344620;1-(6-amino-2-((hydroxy(4-phenylbutyl)phosphinyl)oxy)-1-oxohexyl)proline;111223-26-8;((2S)-6-amino-2-((hydroxy(4-phenylbutyl)phosphoryl)oxy)hexanoyl)-L-proline;CERONAPRIL [MI];SCHEMBL121163;BRN 3635091;DTXSID80891418;D03440;Ceronaprilum;X3MM60SOVP;CERONAPRIL [USAN];Novopril;Ceronapril; SQ 29852;SQ29,852;AKOS040746686;SQ-29852;Ceronapril (USAN/INN);CERONAPRIL [INN];Ceronapril [USAN:INN];UNII-X3MM60SOVP;CERONAPRIL [MART.];428863-50-7;SQ 29852;DA-72097;CHEMBL36503;BDBM50405594;1-[(2s)-6-amino-2-{[hydroxy(4-phenylbutyl)phosphoryl]oxy}hexanoyl]-l-proline;

WJJYZXPHLSLMGE-UHFFFAOYSA-N

1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2

C1N(CCC2=CC=C3C(=C2)C=CC=C3)CC=C(C2=CC=CC(C(F)(F)F)=C2)C1